Suppr超能文献

肝腺瘤的肝移植:一项器官共享联合网络数据库分析及文献系统综述

Liver Transplantation for Hepatic Adenoma: A UNOS Database Analysis and Systematic Review of the Literature.

作者信息

Ziogas Ioannis A, Tasoudis Panagiotis T, Serifis Nikolaos, Alexopoulos Sophoclis P, Montenovo Martin I, Shingina Alexandra

机构信息

Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Vanderbilt University Medical Center, Nashville, TN.

Surgery Working Group, Society of Junior Doctors, Athens, Greece.

出版信息

Transplant Direct. 2022 Jan 5;8(2):e1264. doi: 10.1097/TXD.0000000000001264. eCollection 2022 Feb.

Abstract

BACKGROUND

Liver transplantation (LT) has been employed for hepatic adenoma (HA) on a case-oriented basis. We aimed to describe the characteristics, waitlist, and post-LT outcomes of patients requiring LT for HA.

METHODS

All patients listed or transplanted for HA in the United States were identified in the United Network for Organ Sharing (UNOS) database (1987-2020). A systematic literature review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement.

RESULTS

A total of 199 HA patients were listed for LT in UNOS and the crude waitlist mortality was 9.0%. A total of 142 HA patients underwent LT; 118 of these were among those listed with an indication of HA who underwent LT, and 24 were diagnosed incidentally. Most did not experience hepatocellular carcinoma transformation (89.4%). Over a median follow-up of 62.9 mo, death was reported in 18.3%. The 1-, 3-, and 5-y patient survival rates were 94.2%, 89.7%, and 86.3% in the UNOS cohort. The systematic review yielded 61 articles reporting on 99 nonoverlapping patients undergoing LT for HA and 2 articles reporting on multicenter studies. The most common LT indications were suspected malignancy (39.7%), unresectable HA (31.7%), and increasing size (27.0%), whereas 53.1% had glycogen storage disease. Over a median follow-up of 36.5 mo, death was reported in 6.0% (n=5/84). The 1-, 3-, and 5-y patient survival rates were all 95.0% in the systematic review.

CONCLUSIONS

LT for HA can lead to excellent long-term outcomes in well-selected patients. Prospective granular data are needed to develop more optimal selection criteria and further improve outcomes.

摘要

背景

肝移植(LT)已在个案基础上用于治疗肝腺瘤(HA)。我们旨在描述因HA需要进行LT的患者的特征、等待名单情况及LT后的结局。

方法

在美国器官共享联合网络(UNOS)数据库(1987 - 2020年)中识别所有因HA列入等待名单或接受移植的患者。根据系统评价和Meta分析的首选报告项目声明进行系统文献综述。

结果

UNOS中共有199例HA患者被列入LT等待名单,等待名单上的粗死亡率为9.0%。共有142例HA患者接受了LT;其中118例是在有HA指征的名单上接受LT的患者,24例是偶然诊断出的。大多数患者未发生肝细胞癌转化(89.4%)。中位随访62.9个月时,报告的死亡率为18.3%。在UNOS队列中,1年、3年和5年患者生存率分别为94.2%、89.7%和86.3%。系统综述产生了61篇报告99例非重叠HA患者接受LT的文章以及2篇报告多中心研究的文章。最常见的LT指征是疑似恶性肿瘤(39.7%)、不可切除的HA(31.7%)和体积增大(27.0%),而53.1%的患者患有糖原贮积病。中位随访36.5个月时,报告的死亡率为6.0%(n = 5/84)。在系统综述中,1年、3年和5年患者生存率均为95.0%。

结论

对精心挑选的患者进行HA的LT可带来良好的长期结局。需要前瞻性的详细数据来制定更优化的选择标准并进一步改善结局。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d814/8735769/793871fcae35/txd-8-e1264-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验